Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이윤규 | - |
dc.contributor.author | 장현 | - |
dc.contributor.author | 김범석 | - |
dc.contributor.author | 전상훈 | - |
dc.contributor.author | 박지현 | - |
dc.contributor.author | 박건욱 | - |
dc.contributor.author | 신성훈 | - |
dc.contributor.author | 안호정 | - |
dc.contributor.author | 이경은 | - |
dc.contributor.author | 이근욱 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 김성배 | - |
dc.contributor.author | 안명주 | - |
dc.contributor.author | 황인규 | - |
dc.date.accessioned | 2021-09-23T05:40:32Z | - |
dc.date.available | 2021-09-23T05:40:32Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/49618 | - |
dc.description.abstract | Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한암학회 | - |
dc.title | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 | - |
dc.title.alternative | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 | - |
dc.type | Article | - |
dc.identifier.doi | 10.4143/crt.2020.824 | - |
dc.identifier.bibliographicCitation | Cancer Research and Treatment, v.53, no.3, pp 671 - 677 | - |
dc.identifier.kciid | ART002738438 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000674117200008 | - |
dc.identifier.scopusid | 2-s2.0-85111489644 | - |
dc.citation.endPage | 677 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 671 | - |
dc.citation.title | Cancer Research and Treatment | - |
dc.citation.volume | 53 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Head and neck neoplasms | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | Immune check point | - |
dc.subject.keywordAuthor | Platinum refractory | - |
dc.subject.keywordAuthor | Sum of target lesions | - |
dc.subject.keywordPlus | TO-LYMPHOCYTE RATIO | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | SINGLE-ARM | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | MARKER | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kciCandi | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.